Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Scientists scramble to understand COVID-19 Omicron: What we know

11/29/2021 | 05:12pm EST

Scientists around the world are scrambling to understand the new Omicron variant of COVID-19, identified last week -- its symptoms, severity and contagion.

Governments have reacted with travel restrictions hoping to contain the spread of the variant, which was first identified in South Africa and has since been reported in nearly a dozen countries. No deaths have been linked to the variant.

Scientists have found Omicron's mutations could help it evade immunity -- whether from vaccination or previous COVID-19 infection -- but say more research is needed.

As a result of the new variant's emergence, the Centers for Disease Control and Prevention on Monday revised its COVID-19 vaccine guidelines to recommend booster doses for all adults age 18 and older.

"Existing vaccines are [still] likely to provide a degree of protection against severe cases" of the virus, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement released by the White House on Sunday night.

However, "it will take approximately two more weeks to have more definitive information on the transmissibility, severity and other characteristics of the variant," he said in the statement.

Here's what is known about Omicron so far.

Slightly different symptoms

The first patient infected with the Omicron variant, a 33-year-old man in South Africa, developed "unusual symptoms" compared with those of the Delta strain, Dr. Angelique Coetzee, chairwoman of the South African Medical Association, told the BBC on Sunday.

The patient reported severe fatigue and pain, including a mild headache, for several days prior to testing positive for the virus, she said.

He did not develop a sore throat -- but had a "scratchy" throat -- and did not experience a cough or loss of taste or smell, Coetzee said.

A sore throat, cough and loss of sense of taste or smell are common symptoms of earlier strains of COVID-19, including the Delta variant, which has been the predominant one in the United States since the spring, according to the CDC.

The Delta variant is also known to cause more severe headaches, runny nose and fever.

"Anyone can have mild to severe symptoms" that may appear two to 14 days after exposure to the virus, CDC says.

The symptoms of COVID-19, regardless of variant, include fever or chills, a cough, fatigue, shortness of breath or difficulty breathing, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or a runny nose, nausea or vomiting and diarrhea.

Vaccines and boosters

In the United States, where just under 60% of the eligible population is fully vaccinated, the Biden administration is urging people to get booster doses.

On Monday, the CDC announced that everyone age 18 and older should get a booster shot either when they are six months after their initial Moderna and Pfizer-BioNTech two-dose series or two months following their initial Johnson & Johnson shot.

"The recent emergence of the Omicron variant further emphasizes the importance of vaccination, boosters, and prevention efforts needed to protect against COVID-19," CDC Director, Dr. Rochelle Walensky said in a statement.

"I strongly encourage the 47 million adults who are not yet vaccinated to get vaccinated as soon as possible and to vaccinate the children and teens in their families as well because strong immunity will likely prevent serious illness," she said.

There is no evidence suggesting that the available vaccines from Johnson & Johnson, Moderna and Pfizer-BioNTech will not offer protection against severe illness from the Omicron variant, experts have said.

However, all three manufacturers are testing their vaccines against the new strain and have said they will modify their formulations if needed.

A redeveloped Moderna COVID-19 vaccine that would be effective against the Omicron variant could come as soon as early 2022, Dr. Paul Burton, the company's chief medical officer, said on BBC's Andrew Marr Show on Sunday.

Meanwhile, Pfizer-BioNTech executives told Fox News that they expect to be able to develop and produce a tailor-made vaccine against the variant, if needed, in about 100 days, pending regulatory approval.

Origins of Omicron

Physicians in South Africa first reported seeing patients with symptoms of the new variant on Nov. 18, and it is spreading more rapidly in the region than previous strains, the World Health Organization said.

Omicron has 32 genetic mutations compared to earlier variants of the virus, which may give it "an advantage in transmissibility and that it might evade immune protection" from prior infection or available vaccines, Fauci told NBC on Sunday.

South Africa has seen a "big spike" in COVID-19 cases since early November, with more than 22,000 confirmed infections, according to the country's health department.

Less than 25% of the population there is fully vaccinated against COVID-19, it said.

Since the first case was announced in South Africa, cases have also been found in Britain, Canada, the Czech Republic, Hong Kong, Botswana, Belgium, Germany, Australia and Israel.

Potential for spread

"Even if it's milder than Delta, the increased transmissibility and/or immune escape would still make [Omicron] more dangerous," public health specialist Eric Feigl-Ding told UPI via Twitter.

"Exponentially more cases [means] exponentially more hospitalizations and deaths," said Feigl-Ding, a senior fellow at the Foundation for American Scientists in Washington, D.C.

Although it is likely the variant has already spread globally, the Delta variant is still responsible for most of the current infections globally, the WHO said.

"Over 99% of cases around the world are due to the Delta variant and more deaths are occurring in the unvaccinated," WHO chief scientist Soumya Swaminathan told CNBC's Squawk Box Asia on Monday.

"I think that's our priority while we wait to find out more about [the new] variant," she said.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.38% 170.52 Delayed Quote.-1.57%
MODERNA, INC. -4.63% 147.03 Delayed Quote.-38.99%
All news about MODERNA, INC.
09:38aModerna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
09:19aMODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
09:09aWALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
01/26Moderna starts trial for Omicron-specific booster shot
01/26Moderna starts trial testing Omicron-specific booster shot
01/26MODERNA : Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster C..
01/26Moderna begins testing omicron-matched COVID shots in adults
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 769 M - -
Net income 2021 11 260 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 5,83x
Yield 2021 -
Capitalization 62 828 M 62 828 M -
EV / Sales 2021 2,86x
EV / Sales 2022 1,85x
Nbr of Employees 1 300
Free-Float 90,5%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 154,96 $
Average target price 265,41 $
Spread / Average Target 71,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
CELLTRION, INC.-21.21%18 165